However, contrary to other types of cancers that express EGFR, such as pancreatic cancer, colorectal cancer or head and neck cancer where inhibition of EGFR was successful, attempts to evaluate the benefits of EGFR-inhibitors (both TKI and neutralising antibodies) in metastatic breast cancer have been disappointing [37]. Here, EGFR is linked to pancreatic neoplasm.